Beukers NG, van der Heijden GJ, van Wijk AJ, Loos BG Periodontitis is an independent risk indicator for atherosclerotic cardiovascular diseases among 60 174 participants in a large dental school in the Netherlands. J Epidemiol Community Health. 2017 Jan;71(1):37-42. doi: 10.1136/jech-2015-206745. Epub 2016 Aug 8.
Fox PC and Eversole LR Diseases of the salivary glands. In: Silverman S, Eversole LR, Truelove EL, eds. Essentials of Oral Medicine. Ontario, Canada: BC Decker; 2002:260-276
Friedman PK, Lamster IB Tooth loss as a predictor of shortened longevity: exploring the hypothesis. Periodontol 2000. 2016 Oct;72(1):142-52. doi: 10.1111/prd.12128. Review.
Hajishengallis G, Lamont RJ Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol Oral Microbiol. 2012 Dec;27(6):409-19. doi: 10.1111/j.2041-1014.2012.00663.x. Epub 2012 Sep 3. Review.
Joshy G, Arora M, Korda RJ, Chalmers J, Banks E Is poor oral health a risk marker for incident cardiovascular disease hospitalisation and all-cause mortality? Findings from 172 630 participants from the prospective 45 and Up Study. BMJ Open. 2016 Aug 30;6(8):e012386. doi: 10.1136/bmjopen-2016-012386.
Kaur S, White S, Bartold M Periodontal Disease as a Risk Factor for Rheumatoid Arthritis: A Systematic Review. JBI Libr Syst Rev. 2012;10(42 Suppl):1-12.
Lamster IB Oral health care services for older adults: a looming crisis. Am J Public Health. 2004 May;94(5):699-702.
Lee KH, Plassman BL, Pan W, Wu B Mediation Effect of Oral Hygiene on the Relationship Between Cognitive Function and Oral Health in Older Adults. J Gerontol Nurs. 2016 May 1;42(5):30-7. doi: 10.3928/00989134-20151218-03. Epub 2015 Dec 29.
Lee KH, Wu B, Plassman BL Cognitive function and oral health-related quality of life in older adults. J Am Geriatr Soc. 2013 Sep;61(9):1602-7. doi: 10.1111/jgs.12402. Epub 2013 Aug 26.
Maisonneuve P, Amar S, Lowenfels AB Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Ann Oncol. 2017 May 1;28(5):985-995. doi: 10.1093/annonc/mdx019. Review.
Marsh PD, Zaura E Dental biofilm: ecological interactions in health and disease. J Clin Periodontol. 2017 Mar;44 Suppl 18:S12-S22. doi: 10.1111/jcpe.12679. Review.
Park H, Suk SH, Cheong JS, Lee HS, Chang H, Do SY, Kang JS Tooth loss may predict poor cognitive function in community-dwelling adults without dementia or stroke: the PRESENT project. J Korean Med Sci. 2013 Oct;28(10):1518-21. doi: 10.3346/jkms.2013.28.10.1518. Epub 2013 Sep 25.
Persson RE, Persson GR The elderly at risk for periodontitis and systemic diseases. Dent Clin North Am. 2005 Apr;49(2):279-92. Review.
Shay K Infectious complications of dental and periodontal diseases in the elderly population. Clin Infect Dis. 2002 May 1;34(9):1215-23. Epub 2002 Apr 2.
US Department of Health and Human Services Oral Health in America: A Report of the Surgeon General- Executive Summary. Rockville, MD: US Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, 2000.
Evaluation of a Daily Oral Care Lozenge on Oral Health and Quality of Life in Older Adults
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.